Extensión de la indicación de terapia fotodinámica dirigida vascular con padeliporfina (WST11): resultados de un estudio multicéntrico latinoamericano del cáncer de próstata / Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study

Objetivos: Explorar la proporción de pacientes con cáncer de próstata localizado (CaP) de mayor riesgo que se convertiría en una biopsia negativa con seguridad 12 meses después de la terapia focal no térmica con terapia fotodinámica dirigida vascular de padeliporfina (TFV). Métodos: Estudio multicéntrico en un escenario de antígeno prostático específico (PSA) ≤ 20 ng/ml y patrón 3 de Gleason de volúmenes objetivo de CaP variable o patrón 4 de Gleason secundario de volumen bajo. Todos los pacientes recibieron TFV, que consistió en 4 mg/kg de padeliporfina intravenosa activada por fibras difusoras de luz en la próstata. La próstata se biopsió al inicio del estudio y a los meses 6 y 12. El PSA, los resultados funcionales informados por los pacientes y los cuestionarios de calidad de vida (CdV) se registraron al inicio y a los meses 3, 6 y 12; los eventos adversos (EA) se registraron a lo largo del estudio. Resultados: En la población con intención de tratar (n = 81), la proporción de pacientes con biopsias negativas al mes 12 fue del 74% (60/81 pacientes, IC 95%: 63,1, 83,2%). En la población por protocolo, la proporción fue del 79% (58/73 pacientes, IC 95%: 68,4, 88,0%). Los resultados del cuestionario indicaron una ligera mejoría en la función urinaria y un deterioro limitado en la función sexual. No se observó diferencia en la CdV con el tiempo. Un total de 42/81 (52%) pacientes comunicaron EA leves o moderados y 4 de 81 (4,9%) experimentaron EA graves, todos resueltos sin secuelas. No se informó fototoxicidad, evento cardiovascular, fístula o incontinencia urinaria prolongada, cáncer secundario o muerte. Conclusiones: Los resultados respaldan la eficacia, la seguridad y la CdV asociadas con el tratamiento focal de padeliporfina para el CaP localizado de riesgo bajo/intermedio

Objectives: To explore the proportion of patients with higher risk localized prostate cancer (PCa) that would become safely biopsy negative 12 months after non-thermal focal therapy with padeliporfin vascular-targeted photodynamic therapy (VTP). Methods: Multicenter study in a scenario of prostate-specific antigen (PSA) ≤20ng/ml and variable PCa target volumes Gleason pattern 3 or low-volume secondary Gleason pattern 4, all patients received VTP, consisting of intravenous 4mg/kg padeliporfin activated by light-diffusing fibers in the prostate. The prostate was biopsied at baseline, months 6 and 12, PSA, patient-reported functional outcomes and quality of life (QoL) questionnaires were recorded at baseline, months 3, 6, and 12 and adverse events (AE) throughout the study. Results: In the intention-to-treat population (n = 81), the proportion of patients with negative biopsies at month 12 was 74% (60/81 patients; 95% CI: 63.1%, 83.2%). In the per-protocol population, the proportion was 79% (58/73 patients; 95% CI: 68.4%, 88.0%). Questionnaire results indicated a slight improvement in urinary function and limited deterioration in sexual function. No difference in QoL was observed over time. A total of 42/81 (52%) patients reported mild or moderate and 4 of 81 (4.9%) experienced serious AE, all resolved without sequelae. No phototoxicity, cardiovascular event, fistula or prolonged urinary incontinence, secondary cancer or death was reported. Conclusions: Results support the efficacy, safety, and QoL associated with padeliporfin focal treatment for low/intermediate risk localized PCa

[Urinary catheters prevalence study in a university hospital]. / Enquête de prévalence sur le sondage vésical dans un centre hospitalo-universitaire.

INTRODUCTION: Urinary tract infection is the most common healthcare-association infection, especially because of urinary catheter. We evaluated our practices concerning catheter insertion and management in our institution. MATERIALS AND METHODS: We conducted a single-centre descriptive cross-sectional study during 1 week in September 2014 in all adult departments. We noted prevalence, indications, length, management of urinary catheter (UC) and symptomatic catheter-associated urinary tract infections (SCAUTI). RESULTS: Amongst 1046 patients audited, 125 (12%) had UC. The mean age was 72 years (64.8-79.2). UC prevalence was higher in surgical (88%) and medical (87%) intensive care, urology (50%), geriatrics (18%) and long-term care (18%) departments. The average catheterisation length was 7.8 days (3.8-11.8); it was shorter in surgery than in medicine departments (3.6 vs 9.7 days, P<0.001). Catheters were present for more than 4 days in 60% of the cases. Acute urinary retention was the most frequent indication (59%), significantly more in medical than surgical departments (75% vs 26%). Others indications were perioperative (17%), diuresis monitoring (12%), strict immobilization (4%) and unnecessary indications or staff comfort (4%). A SCAUTI was present in 10% of cases, mostly in medicine department (30% vs 8%). CONCLUSION: The prevalence of our institution is higher than the national prevalence (8.1%), but still below the European average (17.2%). Control of the risk of CAUTI requires compliance with UC appropriate indications, UC management, and prompt removal of unnecessary UC. LEVEL OF EVIDENCE: 4.

[Clinical impact of the intravesical prostatic protrusion: a review by the LUTS committee of the French Urological Association]. / Impact en pratique clinique de l'indice de protrusion prostatique intravésicale: une revue de la littérature du CTMH de l'AFU.

INTRODUCTION: Intravesical prostatic protrusion (IPP) is a protrusion of the lateral and/or median prostatic lobes into the bladder lumen. IPP can be estimated by suprapubic ultrasound. METHODS: A literature search was conducted in Pubmed/MEDLINE database using the following keywords: intravesical prostatic protrusion; benign prostatic enlargement; treatment outcome; ultrasonography. RESULTS: There are 3 grades of IPP: grade 1, 2 and 3 respectively if IPP ≤ 5mm, if 5-10mm, and if >10mm. IPP was a better prognosis factor than PSA and prostate volume for bladder outlet obstruction (BOO) with a sensibility of 80% and a sensitivity of 68% for grade 3. The progression risk of BOO increased with IPP (grade 1: OR=5.1 [95%CI: 1.6-16.2] and grade ≥ 2 OR=10.4 [95%CI: 3.3-33.4]). IPP was a predictive marker of failure of trial off catheter in patients with acute urinary retention with a 6 folds higher risk for grades ≥ 2. IPP was a prognosis factor for tamsulosine efficacy: 78% of patients with grade ≤ 2 had an improvement >35% of the IPSS-score versus 58% for grade >3 (P<0.01). Patients with grade >3 and a PV< 40cc had a poorer response to tamsulosine. After TURP, IPSS was more improved for grade ≥ 1 with an OR=3.43 (95%CI: 1.03-11.44, P=0.045). CONCLUSION: IPP can be a useful marker for the management of LUTS/BPH.

[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years]. / Évaluation de la prise en charge du cancer du rein métastatique à l'ère des thérapies ciblées. Étude clinique rétrospective sur six ans.

OBJECTIVE: To evaluate the outcomes following targeted therapies in the management of metastatic renal cell carcinoma (mRCC), through the study of overall survival (OS) and progression-free (PFS). PATIENTS AND METHODS: We retrospectively included 78 patients treated with targeted therapies for mRCC at the Paul Papin Cancer Institute from 2004 to 2009. Overall survival (OS), progression free survival (PFS), response to treatment, occurrence of grade III and IV side effects, were analyzed following first and second line treatments. RESULTS: Median follow-up was 33 months [5-236], and 41 patients died (52.6%). Median OS was 36 months [95% CI 29-43]. The median PFS was 14 months [95% CI 6.71-21.29] for sunitinib, 38 months [95% CI 11.41-64.59] for bevacizumab with interferon (IFN), and 8 months [95% CI 0-17.03] for IFN alone. A partial reduction, stabilization or increase in tumor size was observed for 19.2%, 47.4% and 25.6% of cases. A second line treatment was given for 53 patients. They received either sunitinib (n=20, 37.8%), bevacizumab with IFN (n=7, 13.2%), sorafenib (n=17, 32.2%), temsirolimus (n=3, 5.6%) or other molecules (n=6 11.2%). Grade III or IV side effects were observed for 14.1%, 28.3% and 18.2% of the patients following first, second and third line treatment, respectively. CONCLUSION: Outcomes of targeted therapies in our center upheld the literature data. These therapies allow a benefit survival versus immunotherapy, with sometimes large side-effect.

[Androgen deprivation and cardiovascular risk in prostate cancer treatment]. / Hormonothérapie et risque cardiaque dans le traitement des cancers prostatiques.

Androgen suppression clearly increases the occurrence of cardiovascular risk factors : increased body fat, dyslipidemia and type II diabetes. Thus, several studies (but not all), showed an increase in coronary artery disease but also of sudden death and ventricular arrhythmias in relation to androgen deprivation, even for a short duration. This risk is particularly important in patients with existing cardiovascular risk factors or a history of heart disease. Cardiovascular risk should be balanced with the benefit of androgen deprivation on overall survival, especially when it is proposed in adjuvant setting, combined with radiotherapy in locally advanced prostate tumors. In practice, it is recommended that patients be referred to their physician for an evaluation before starting treatment, then 3 to 6 months after starting treatment, then once a year. The initial assessment should include: a clinical examination (with measurement of blood pressure and body index) and laboratory test with full lipid profile (total cholesterol, HDL and LDL cholesterol, triglycerides) and glucose. It is also important that patients with heart disease, receive lifestyle advice and low- dose aspirin (80 mg/day).

[Surgical management of benign prostatic hyperplasia by endoscopic techniques using electricity and open prostatectomy: A review of the literature by the LUTS committee of the French Urological Association]. / Traitement de l'hyperplasie bénigne de prostate par techniques endoscopiques électriques et adénomectomie voie haute : revue de littérature du CTMH de l'AFU.

PURPOSE: To perform an update on the surgical treatment of benign prostatic hyperplasia (BPH) by endoscopic electric resection and vaporization, and by open prostatectomy. METHOD: A systematic review of recent literature was performed. The level of evidence of each report was evaluated, and only recent publications of high level of evidence were included. RESULTS AND CONCLUSIONS: Both monopolar transurethral resection of the prostate (TURP) and open prostatectomy remain the gold standards. Endoscopic electric alternatives are monopolar and bipolar prostate vaporisation as well as bipolar resection. These techniques seem to show similar functional results than TURP and open prostatectomy, as well as an advantage in terms of bleeding.

[Postpartum urinary retention]. / Rétention vésicale du post-partum.

Postpartum urinary retention is an uncommon event that occurs in 0.7 to 0.9% of vaginal deliveries. An ignorance of this situation can lead to delayed diagnosis worsening the prognosis and to inadequate treatments. This complication is defined as the absence of spontaneous micturition within 6hours of vaginal delivery with a bladder volume above 400mL. The etiology depends on multiple factors. Because of physiological changes during pregnancy, the bladder is hypotonic with an increased post-void residual volume. The occurrence of a perineal neuropathy during delivery may cause a urinary retention. Risk factors are primiparity, prolonged labour, instrumental delivery and perineal lacerations. Treatment consists on clean intermittent catheterization and recovery occurs generally in 72hours. Persistent urinary retention is the principal short-term complication and should be treated by clean intermittent self-catheterization. Long-term consequences are poorly reported in the literature.

[How radical nephrectomy compares to partial nephrectomy for the treatment of pT1a papillary renal cell carcinomas?]. / Comment se comparent néphrectomies partielles et élargies pour le traitement des carcinomes papillaires pT1aN0M0? Etude comparative rétrospective de 277 cas.

PURPOSE: Our objective was to compare oncologic results of nephron sparing surgery (NSS) versus radical nephrectomy (RN) in T1aN0-x M0 papillary renal cell carcinoma (PRCC). PATIENTS AND METHODS: We retrospectively reviewed 277 patients treated for a pT1aN0M0 PRCC selected from an academic database from 12 centres. We compared the clinico-pathological features by using Chi-square and Student statistical analyses. Survivals analyses using Kaplan-Meier and Log-rank models were performed. RESULTS: The two groups were composed by 186 patients treated by NSS and 91 by RN. The TNM stage was fixed and the two groups were, in terms of age and Fuhrman grade, comparable. Median age at diagnosis was 59 years (27-85). Median tumor size was 2.7 cm (0.4-4). The average follow-up was 49 months (1-246). Very few events arose in both groups: two local recurrences were observed in the NSS group (1.07%), three patients died of cancer in the NSS treated group (1.6%) and five in the RN treated group (5.5%). The five and 10 cancer-specific survival rate were comparable in the two groups (98% vs. 100% and 98% vs. 97%). The specific survival curves were perfectly similar for both groups (log rank test, p=0.25). CONCLUSION: NSS is equivalent to RN as far as oncologic control of pT1aN0M0 PRCC is concerned.

[Teaching and perception of urology by medical students at the end of the second cycle: an appraisal]. / Enseignement et perception de l'urologie à la fin du deuxième cycle des études médicales: état des lieux.

OBJECTIVES: Our purpose was to determine how the medical students from the second cycle perceived urology and what their learning methods were. MATERIAL AND METHODS: An e-questionnaire was sent to 1600 students in 16 teaching faculties during the last year of their second cycle. RESULTS: Overall, we obtained 590 answers (36.8%). In our population, 70.2% of the students were women. Of them, 24.1% had been already enrolled in an academic urology unit. Urology was defined as a medical, surgical and medico-surgical discipline by 3.7%, 37.8% and 58% of the students, respectively. Urology was considered as very important, important, not very important and not important at all by 5.1%, 54.4%, 37.5% and 2.4% of the students. The teaching methods used to learn urology were duplicated-notes for ENC preparation (45.3%), conferences for ENC (French national ranking exam) preparation (43.7%), courses of the national urology college (38.6%) and courses of the faculty (32%). The best mastered items were lithiasis disease (86.3%), voiding dysfunction (76.3%) and urological cancers (56.7%). On the contrary, only 34.7% and 28% considered their knowledge sufficient on the erectile dysfunctions and on renal transplantation. Lastly, 7.3% intended to become urologists. Having a work experience in a urology unit was significantly associated to the feeling of being prepared to become an intern (p<0.001) and to the project of becoming a urologist (p<0.001). CONCLUSION: Urology was considered like an important discipline by half of the students at the end of the second cycle even though it is under-represented in the national teaching programme for ENC. A third of the students used courses from the faculty to learn urology and a quarter of them had a work experience in a urology unit during their second cycle.

[Prognostic value of erythrocyte polyamines levels in renal cell carcinoma. Prospective study in 418 cases]. / Valeur pronostique des polyamines érythrocytaires dans le cancer du rein. Etude chez 418 patients.

OBJECTIVES: Polyamines: Spermine (Spm) and Spermidine (Spmd), are essential for cell proliferation and differentiation. A measurement of erythocytes polyamines (EPA) was developed in our institution. Our objective was to evaluate this marker as a new prognostic factor in renal cell carcinoma. PATIENTS AND METHODS: A blood sample was prospectively taken before surgery, among 418 patients who had an enlarged nephrectomy (n=318) or a partial nephrectomy (n=100) to quantify EPA rates by using the HPLC technique. The qualitative and quantitative variables have been compared using chi(2) and Student statistical analyses. The survivals have been normalized by the Kaplan Meier and Cox methods. RESULTS: The average age of our population was 64 years (21-88). The average decline was 41 months (1-214). The median size of tumors was 6.5cm (1-24). The median rate of Spm and Spmd were respectively 4.7 (1-83) and 9 (2-86)nmol/8.10(9) erythrocytes. Spm and Spmd were linked to the T stage (p=0.001), and the ECOG (p=0.001 and 0,008). Spm was not linked at N and M stages but at the Fuhrman grade (p=0.001). Spmd was linked to the N, M stages (p=0.04). With univariate analysis, the tumor diameter, the TNM stage, the Fuhrman grade as well as Spm and Spmd (p<0.0001) were predictors of specific survival. With multivariate analysis, some prognostic factors remained independent: the TNM stage, the ECOG and Spmd, a continuous variable (p=0.0001), pushing the rank of Fuhrman out of the model. When Spm and Spmd were dichotomized in quantitative variables, they were both independent factors. CONCLUSION: The EPA is a new prognostic tool, before surgery, which will be tested for its integration into prognostic normograms.

[Diagnostic and therapeutic management of the benign prostatic hyperplasia by the general practitioners in the Maine-et-Loire]. / Evaluation des pratiques des médecins généralistes du Maine et Loire concernant l'hypertrophie bénigne de la prostate.

AIM: To assess the diagnosis and therapeutic management of the benign prostatic hyperplasia (BPH) by the general practitioners (GPs) in the Maine-et-Loire. PATIENT AND METHODS: A questionnaire evaluating the management of BPH was sent to the 686 GPs of the Maine-et-Loire between March and June 2008. RESULTS: One hundred and seventy-one GPs answered. Among them 24% were women, 35.1% worked in urban areas, 34.5% worked in semi-urban areas and 30.4% worked in rural areas. 17.5 % had been working less than 10 years, 29.2% had been working between 10 and 20 years and 53.2% had been working more than 20 years. The medical interview, the digital rectal examination (DRE) and the assay of the prostatic serum antigen (PSA) were performed by more than 90% of the GPs whereas the ultrasound scan and the international prostatic score symptom (IPSS) were respectively used by only 15,2 and 69,6% of them. Phytotherapy, alphablockers and inhibitors of 5 alpha reductase were respectively prescribed by 85.4, 95.3 and 53.8% of the GPs. 96.5% of the GPs addressed the patient to a urologist after the failure of the first line treatment. There were no differences according to the working environment. Women performed less DRE (p<0.0001) and sent more patients to urologist than men (p=0.0197). Finally, 88.9% of the GPs were interested in having an update on the last recommendations. CONCLUSION: The GPs diagnosed BPH and initiated the first line treatment. In case of failure, they sent the patients to a urologist. Their primary treatment management was not really in adequation with the recommendations. The recent therapeutic innovations may explain this discordance between the clinical practice and the recommendations. It is noteworthy that most of the GPs who answered this survey were keen in having an update on the recent advances in the BPH management.

[Review of literature concerning the use of laser treatment for symptomatic BPH]. / Revue de la littérature sur l'utilisation des lasers pour le traitement de l'HBP symptomatique.

Even if transurethral resection of the prostate (TURP) today remains the referential surgery in the treatment of symptomatic benign prostatic hyperplasia (BPH), the last decade has seen the emergence of considerable improvements in light amplification by stimulated emission of radiation (LASER) technology. Better understanding of the interaction between the different wavelengths of these lasers and tissue has enabled the development of new and promising types of treatment. This article, through a review of published literature, attempts first of all to retrace the history of this technique in the treatment of symptomatic BPH and then goes on to give an update on results and new aspects of the different types of laser used.

[Evidence-based medicine and French medical students: an appraisal]. / Evidence-based medicine et étudiants en médecine français : état des lieux.

INTRODUCTION: Nowadays, evidence-based medicine (EBM) is essential to learn and to practice medicine. The aim of the current study was to investigate the baseline level of knowledge of French students regarding EBM. MATERIALS AND METHODS: Between April and May2008, a questionnaire was sent by e-mail to 900students in their last year of medical study. RESULTS: On 327 answers, 297 (91%), 94 (29%) and 85 (26%) students declared they read, write and speak medical English. Ninety (28%) read an article of a French medical review once a month and 43 (13%) read an article of an international medical review once a month. Three hundred and eleven (95%) knew the bases of medical research on the Internet and 219 (67%) used them. Twenty-four (7%) had already participated in a editorial staff of a medical article, 7 (2%) had been co-authors. Two hundred and seventy-two (83%) had made an oral presentation during a medical staff and 3 (1%) during a congress. Finally, 237 (73%) understood the interest of the critical analysis of an article at the ECN and 70 (21%) thought they were prepared. CONCLUSION: The incapacity of learning EBM is one of the limits of the French medical training system. The introduction of the reading critical of an article at the ECN is the concrete beginning of an answer to this problem.

[Genetic determinants of anatomical variants of the prostate]. / Facteurs génétiques déterminant les variations anatomiques de la prostate.

INTRODUCTION: The determinants of macroscopic and microscopic anatomical variants of the prostate during ageing are poorly defined. The authors evaluated the correlation between specific gene polymorphisms involved in androgen and oestrogen synthesis and gross (prostatic weight) and microscopic anatomy (stroma/epithelium ratio) of the prostate during ageing. METHODS: The prostatic weight and stromal surface area of an autopsy series of 85 men over the age of 50 were measured, then compared as a function of gene polymorphisms involved in androgen or oestrogen regulation. The following polymorphisms were studied: number of CAG repeats of the androgen receptor (AR), number of TA repeats and the V89L variant of the 5-alpha-reductase gene (SRD5A2) for androgens, and the A1A2 variant of 17-alpha-hydroxylase (CYP17) and number of TTTA repeats of the aromatase (CYP19) for oestrogens. RESULTS: No correlation was observed between the number of TA repeats of the SRD5A2 gene or TTTA repeats of the CYP19 gene and anatomical parameters of the prostate. A statistically significant positive correlation was observed between age and prostate weight (r=0.21, p=0.05) and a statistically significant negative correlation was observed between prostate weight and number of CAG repeats (r=-0.32, p=0.003). The group with less than 20 CAG repeats was associated with a higher prostate weight than the other group. The stromal surface area was greater in the [20-23] CAG repeat group (p=0.02), and in the A2A2 group of CYP17 (p=0.016) than in the other groups. CONCLUSION: A small number of CAG repeats is associated with a higher prostate weight. The mean number of CAG repeats of the androgen receptor and the A2A2 variant of the CYP17 gene are associated with a larger stromal surface area.

[Management of male urinary incontinence after radical prostatectomy (CTMH AFU 2006 - 4/5): place of intraurethral macroplastique injection, artificial urinary sphincter and cell therapy]. / Prise en charge d'une incontinence urinaire masculine après prostatectomie radicale (CTMH AFU 2006 - 4/5): place de l'injection intra-urétrale de macroplastique, du sphincter urinaire artificiel et des thérapies cellulaires.

The management of moderate urinary incontinence after radical prostatectomy may require the use of an artificial sphincter, which remains the reference technique although it requires implantation of material, sometimes involving redo operations. Submucosal macroplastique injections have been proposed, but the results do not appear to be maintained over time. Cell therapy, consisting of the injection of stem cells into or close to the sphincter, probably represents the approach of the future, but in 2006, studies were still only at the evaluation phase.

[Management of male urinary incontinence after radical prostatectomy (CTMH AFU 2006 - 5/5). Prevention of incontinence and CTMH guidelines]. / Prise en charge d'une incontinence urinaire masculine après prostatectomie radicale (CTMH AFU 2006 - 5/5) Prévention de l'incontinence et recommandations du CTMH.

Preservation of continence essentially depends on the operator and the quality of the operative procedure. The number of publications on this subject reflects the desire of urologists to provide their patients not only with control of the cancer but also preservation of their sexual and urinary functions. Ideally, surgery should preserve the striated sphincter and levator muscles, the neurovascular pedicles when oncologically acceptable, and the bladder neck and a leak-proof anastomosis must be ensured. The surgeon must satisfy two imperatives to achieve these objectives: a good knowledge of anatomy and meticulous preservation of this anatomy from the beginning to the end of the operation by highly selective dissection in selected patients. Finally, the Comité des Troubles Mictionnels de l'Homme (Male Voiding Disorders Committee) proposes guidelines for the diagnosis and treatment of urinary incontinence after radical prostatectomy.

[Management of male urinary incontinence after radical prostatectomy (CTMH AFU 2006-1/5): incidence and role of urodynamic assessment and electromyography]. / Prise en charge d'une incontinence urinaire masculine après prostatectomie radicale (CTMH AFU 2006-1/5): incidence et rôle du bilan urodynamique et de l'électromyogramme.

The incidence of postprostatectomy urinary incontinence varies according to the technique used, over time and according to the type of management, with an incidence at one year ranging from just a few percent to more than 60%. Assessment is required in the case of persistent disabling urinary incontinence despite well conducted perineal rehabilitation one year after surgery or earlier in the case of severe incontinence. Urodynamic assessment is the essential examination to quantify urethral closure pressure. A review of the literature of urodynamic assessment and electromyography is presented.

[Management of male urinary incontinence after radical prostatectomy (CTMH AFU 2006-2/5): place of perineal rehabilitation and medical treatment]. / Prise en charge d'une incontinence urinaire masculine après prostatectomie radicale (CTMH AFU 2006-2/5): place de la rééducation périnéale et du traitement médical.

The treatment of incontinence is changing, but perineal rehabilitation still plays an essential role and is usually able to rapidly and effectively improve urinary incontinence. Medical treatment modalities are fairly limited: anticholinergic drugs have a limited efficacy except in the case of unstable bladder demonstrated by urodynamic assessment and, despite encouraging preliminary results, duloxetine has not obtained scientific recognition or marketing authorization.

[Management of male urinary incontinence after radical prostatectomy (CTMH AFU 2006-3/5): place of periurethral balloon and suburethral tape]. / Prise en charge d'une incontinence urinaire masculine après prostatectomie radicale (CTMH AFU 2006-3/5): place des ballons périurétraux et des bandelettes sous uréthrales.

The treatment of incontinence is changing. Perineal rehabilitation still plays an essential role, but new modalities are now available with promising results, particularly periurethral balloon and suburethral tape, which may be indicated after failure of well-conducted perineal rehabilitation and before artificial sphincter. Periurethral balloons consist of two silicone balloons filled with a mixture of saline and radiopaque agent inserted transperineally on either side of the urethra as close as possible to the bladder neck. Titanium ports connected to each balloon allow adjustment of the volume contained in the balloon at any time after surgery. This technique appears to be promising but further studies are required to clearly define many unresolved issues, including results based on longer follow-up and patient selection according to the severity of incontinence or their treatment history (radiotherapy). Suburethral tape is used to exert permanent static compression of the urethra and was still under development in 2006. Fairly heterogeneous materials are used and no consensus on this issue has yet been reached. Follow-up is still relatively short and few studies have addressed the problem of patient selection. Some authors consider that the best indication is mild-to-moderate incontinence, which has not yet been clearly defined.

Clinical relevance of genetic instability in prostatic cells obtained by prostatic massage in early prostate cancer.

We investigated whether genetic lesions such as loss of heterozygosity (LOH) are detected in prostatic cells obtained by prostatic massage during early diagnosis of prostate cancer (CaP) and discussed their clinical relevance. Blood and first urine voided after prostatic massage were collected in 99 patients with total prostate-specific antigen (PSA) between 4 and 10 ng ml(-1), prior to prostate biopsies. Presence of prostatic cells was confirmed by quantitative RT-PCR analysis of PSA mRNA. Genomic DNA was analysed for LOH on six chromosomal regions. One or more allelic deletions were found in prostatic fluid from 57 patients analysed, of whom 33 (58%) had CaP. Sensitivity and specificity of LOH detection and PSA free to total ratio <15% for positive biopsy were respectively 86.7 and 44% (P=0.002) for LOH, and 55 and 74% (P=0.006) for PSA ratio <15%. Analysis of LOH obtained from prostatic tumours revealed similar patterns compared to prostatic fluid cells in 86% of cases, confirming its accuracy. The presence of LOH of urinary prostatic cells obtained after prostatic massage is significantly associated with CaP on biopsy and may potentially help to identify a set of patients who are candidates for further prostate biopsies.